CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Net Inc. Y/Y Annual
Embecta Corp   (EMBC)
Other Ticker:  
 
 

EMBC's Net Income Growth by Quarter and Year

Embecta 's Net Income results by quarter and year




EMBC Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter September - 6.00 81.60 0.00
III Quarter June 14.70 15.20 62.40 0.00
II Quarter March 28.90 14.00 79.60 0.00
I Quarter December 20.10 35.20 0.00 0.00
FY   63.70 70.40 223.60 0.00



EMBC Net Income third quarter 2024 Y/Y Growth Comment
Embecta Corp reported decrease in Net Income in the third quarter 2024 by -3.29% to $ 14.70 millions, from the same quarter in 2023.
Despite modest results in the third quarter 2024, contraction in Embecta Corp 's Net Income appears to be smaller than Company's recent average decline.

Looking into third quarter 2024 results within Medical Equipment & Supplies industry 26 other companies have achieved higher Net Income growth. While Embecta Corp ' s Net Income decline of -3.29% ranks overall at the positon no. 959 in the third quarter 2024.


EMBC Net Income ( Y/Y Growth %) 2024
 2023 2022 2021
IV Quarter September - -92.65 % - -
III Quarter June -3.29 % -75.64 % - -
II Quarter March 106.43 % -82.41 % - -
I Quarter December -42.9 % - - -
FY   - -68.52 % - -

Financial Statements
Embecta 's third quarter 2024 Net Income $ 14.70 millions EMBC's Income Statement
Embecta 's third quarter 2023 Net Income $ 15.20 millions Quarterly EMBC's Income Statement
New: More EMBC's historic Net Income Growth >>


EMBC Net Income (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
IV Quarter September - -60.53 % 30.77 % -
III Quarter June -49.13 % 8.57 % -21.61 % -
II Quarter March 43.78 % -60.23 % - -
I Quarter December 235 % -56.86 % - -
FY (Year on Year)   - -68.52 % - -


Compare EMBC Profitability >> Back to EMBC Growth rate Comparisons >>


Net Income third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #27
Healthcare Sector #60
Overall #959

Net Income Y/Y Growth Statistics
High Average Low
106.43 % -31.74 % -92.65 %
(Mar 31 2024)   (Sep 30 2023)
Net Income third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #27
Healthcare Sector #60
Overall #959
Net Income Y/Y Growth Statistics
High Average Low
106.43 % -31.74 % -92.65 %
(Mar 31 2024)   (Sep 30 2023)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Embecta 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
235 % 7.75 % -60.53 %
(Dec 31 2023)  


EMBC's III. Quarter Q/Q Net Income Comment
In the III. Quarter 2024 Embecta Corp disclosed fall in Net Income from the second quarter by -49.13% to $ 14.70 millions, from $ 28.90 millions released a quarter before.

Even cyclical factors were not able to recover the III. Quarter for the Embecta Corp , Amber  Johnson, a business contributor wrote, she detected additional difficulties onward for the Medical Equipment & Supplies's company and continued that average quarter on quarter Net Income growth is at 7.75% for the Medical Equipment & Supplies's company.

Within Medical Equipment & Supplies industry 26 other companies have achieved higher Net Income quarter on quarter growth. While Embecta 's Net Income growth quarter on quarter, overall rank is 1087.


Net Income Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #27
Healthcare Sector #70
Overall #1087
Net Income Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #27
Healthcare Sector #70
Overall #1087
Net Income Q/Q Growth Statistics
High Average Low
235 % 7.75 % -60.53 %
(Dec 31 2023)  


EMBC's III. Quarter Q/Q Net Income Comment
In the III. Quarter 2024 Embecta Corp reported fall in Net Income from the previous quarter by -49.13% to $ 14.70 millions, from $ 28.90 millions declared in the previous quarter.

Albeit periodic influence usually fuel III. Quarter 2024 performance, this simply has not been substantial to recover Embecta 's III. Quarter performance, Amber  Johnson, a business contributor wrote.

Within Medical Equipment & Supplies industry 26 other companies have achieved higher Net Income quarter on quarter growth. While Embecta 's Net Income growth quarter on quarter, overall rank is 1087.


Embecta 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Net Income 12 Months Ending $ 69.70 $ 70.20 $ 55.30 $ 70.40 $ 146.00
Y / Y Net Income Growth (TTM) -52.26 % -63.66 % -78.63 % - -
Year on Year Net Income Growth Overall Ranking # 1110 # 1449 # 331 # 0 # 0
Seqeuential Net Income Change (TTM) -0.71 % 26.94 % -21.45 % -51.78 % -24.43 %
Seq. Net Income Growth (TTM) Overall Ranking # 822 # 1048 # 257 # 1347 # 1259

New: More EMBC's historic Net Income Growth >>



Cumulative Net Income growth Comment
Embecta showed decline, but improvement compare to trailing twelve month Net Income decrease in Mar 31 2024. If the fiscal year would end in Jun 30 2024, Embecta 's annual Net Income fall would be -52.26% year on year to $70 millions.

In the Healthcare sector 77 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 1110, from total ranking in previous quarter at 1449.

Net Income TTM Q/Q Growth Statistics
High Average Low
-52.26 %
-64.85 %
-78.63 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 21
Healthcare Sector # 78
Overall # 1110

Net Income TTM Y/Y Growth Statistics
High Average Low
-52.26 %
-64.85 %
-78.63 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 59
S&P 500 # 822
Cumulative Net Income growth Comment
Embecta showed decline, but improvement compare to trailing twelve month Net Income decrease in Mar 31 2024. If the fiscal year would end in Jun 30 2024, Embecta 's annual Net Income drop would be -52.26% year on year to $70 millions.

In the Healthcare sector 77 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 1110, from total ranking in previous quarter at 1449.

Net Income TTM Q/Q Growth Statistics
High Average Low
-52.26 %
-64.85 %
-78.63 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 21
Healthcare Sector # 78
Overall # 1110

Net Income TTM Y/Y Growth Statistics
High Average Low
-52.26 %
-64.85 %
-78.63 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 59
S&P 500 # 822




Other Net Income Growth
Medical Equipment & Supplies Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
EMBC's Net Income Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for EMBC's Competitors
Net Income Growth for Embecta 's Suppliers
Net Income Growth for EMBC's Customers

You may also want to know
EMBC's Annual Growth Rates EMBC's Profitability Ratios EMBC's Asset Turnover Ratio EMBC's Dividend Growth
EMBC's Roe EMBC's Valuation Ratios EMBC's Financial Strength Ratios EMBC's Dividend Payout Ratio
EMBC's Roa EMBC's Inventory Turnover Ratio EMBC's Growth Rates EMBC's Dividend Comparisons



Companies with similar Net Income drop for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2024
Biogen Inc -1.63%$ -1.635 millions
Embecta Corp -3.29%$ -3.289 millions
Quest Diagnostics Inc-3.61%$ -3.614 millions
Abbott Laboratories-5.31%$ -5.309 millions
Zoetis Inc -6.87%$ -6.866 millions
Idexx Laboratories Inc-9.34%$ -9.337 millions
Prestige Consumer Healthcare Inc -11.89%$ -11.893 millions
Align Technology inc -13.64%$ -13.639 millions
National Research Corporation-15.10%$ -15.097 millions
Dariohealth Corp -17.94%$ -17.938 millions
Bristol myers Squibb Company-18.92%$ -18.922 millions
Organon and Co -19.42%$ -19.421 millions
U S Physical Therapy Inc-21.21%$ -21.206 millions
Fonar Corporation-25.01%$ -25.010 millions
Pacira Biosciences inc -26.69%$ -26.693 millions
Privia Health Group Inc -27.00%$ -26.997 millions
West Pharmaceutical Services Inc -28.24%$ -28.240 millions
Neurocrine Biosciences Inc -31.94%$ -31.937 millions
Abbvie Inc -32.26%$ -32.264 millions
Lifevantage Corp-33.62%$ -33.622 millions
Lantheus Holdings Inc -34.06%$ -34.057 millions
Viemed Healthcare Inc -36.61%$ -36.609 millions
Vaso Corporation-44.26%$ -44.257 millions
Nature s Sunshine Products inc -44.42%$ -44.415 millions
Royalty Pharma Plc-44.67%$ -44.675 millions
Globus Medical Inc -44.97%$ -44.968 millions
Amgen Inc -45.90%$ -45.903 millions
Elite Pharmaceuticals Inc -46.07%$ -46.070 millions
Surgery Partners Inc -50.78%$ -50.780 millions
Radnet Inc -52.29%$ -52.294 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com